HEPATIC TM6SF2 SUPRRESSES NAFLD-HCC THROUGH ACTIVATING ANTITUMOR IMMUNITY

被引：0
|
作者：
Zhang, Yating
Xie, Mingxu
Liu, Weixin
Liang, Cong
Wen, Jun
Yu, Jun
Zhang, Xiang
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1559
引用
收藏
页码：S1414 / S1414
页数：1
相关论文
共 50 条
  • [31] NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects
    Sliz, Eeva
    Sebert, Sylvain
    Wurtz, Peter
    Kangas, Antti J.
    Soininen, Pasi
    Lehtimaki, Terho
    Kahonen, Mika
    Viikari, Jorma
    Mannikko, Minna
    Ala-Korpela, Mika
    Raitakari, Olli T.
    Kettunen, Johannes
    HUMAN MOLECULAR GENETICS, 2018, 27 (12) : 2214 - 2223
  • [32] REGULATION OF TM6SF2 BY MICRORNA-432: A POTENTIAL THERAPEUTIC TARGET
    Aziziraftar, Shahrbanoo Keshavarz
    Mehraban, Mohammad
    Peaslee, Caitlin
    Somayaji, Medha
    Duwaerts, Caroline
    Le Guillou, Dounia
    Maher, Jacquelyn
    Mattis, Aras
    HEPATOLOGY, 2024, 80 : S101 - S102
  • [33] New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer
    Jiang, Xiaoxiao
    Qian, Hui
    Ding, Wen-Xing
    HEPATOLOGY, 2021, 74 (03) : 1141 - 1144
  • [34] Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism
    Liu, Jing
    Ginsberg, Henry N.
    Reyes-Soffer, Gissette
    CURRENT OPINION IN LIPIDOLOGY, 2024, 35 (03) : 157 - 161
  • [35] OPPOSING EFFECTS OF TM6SF2 GENOTYPE ON HEPATIC AND CARDIAC OUTCOMES BASED ON CLINICAL RISK FACTORS IN THE UK BIOBANK
    Chen, Vincent L.
    Oliveri, Antonino
    Raut, Chinmay
    Chen, Yanhua
    Cushing-Damm, Kelly
    Speliotes, Elizabeth
    GASTROENTEROLOGY, 2024, 166 (05) : S1623 - S1623
  • [36] TM6SF2 E167K variant increases the severity of NAFLD in high fat diet-fed mice
    Liu, Shousheng
    Sun, Baokai
    Zhang, Jie
    Zhang, Qing
    Xin, Yongning
    JOURNAL OF HEPATOLOGY, 2020, 73 : S680 - S681
  • [37] Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy
    Zhang, Yating
    Xie, Mingxu
    Wen, Jun
    Liang, Cong
    Song, Qian
    Liu, Weixin
    Liu, Yali
    Song, Yang
    Lau, Harry Cheuk Hay
    Cheung, Alvin Ho-Kwan
    Man, Kwan
    Yu, Jun
    Zhang, Xiang
    GUT, 2024,
  • [38] The overexpression of TM6SF2 and/or MBOAT7 wild-type genes restores the mitochondrial lifecycle and activity in an in vitro NAFLD model
    Paolini, Erika
    Longo, Miriam
    Meroni, Marica
    Tria, Giada
    Piciotti, Roberto
    Ruscica, Massimiliano
    Fracanzani, Anna Ludovica
    Dongiovanni, Paola
    JOURNAL OF HEPATOLOGY, 2023, 78 : S802 - S803
  • [39] PNPLA3 but not TM6SF2 polymorphisms were associated with higher degrees of steatosis and liver fibrosis among Brazilian NAFLD patients
    Mazo, Daniel F.
    Malta, Fernanda
    Stefano, Jose Tadeu
    Salles, Ana Paula M.
    Gomes-Gouvea, Michele S.
    Nastri, Ana Catharina S.
    Almeida, Jazon Romilson S.
    Pinho, Joao Renato R.
    Carrilho, Flair J.
    Oliveira, Claudia P.
    HEPATOLOGY, 2017, 66 : 1159A - 1159A
  • [40] The overexpression of TM6SF2 and/or MBOAT7 wild-type genes restores the mitochondrial lifecycle and activity in an in vitro NAFLD model
    Paolini, E.
    Longo, M.
    Meroni, M.
    Tria, G.
    Piciotti, R.
    Ruscica, M.
    Fracanzani, A. L.
    Dongiovanni, P.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S33 - S33
12345